Medusins: A new class of antimicrobial peptides from the skin secretions of phyllomedusine frogs

Biochimie ◽  
2013 ◽  
Vol 95 (6) ◽  
pp. 1288-1296 ◽  
Author(s):  
Xinping Xi ◽  
Renjie Li ◽  
Yingchun Jiang ◽  
Yan Lin ◽  
Yuxin Wu ◽  
...  
2014 ◽  
Vol 77 (4) ◽  
pp. 831-841 ◽  
Author(s):  
Alvaro Siano ◽  
María Verónica Húmpola ◽  
Eliandre de Oliveira ◽  
Fernando Albericio ◽  
Arturo C. Simonetta ◽  
...  

Author(s):  
J. Michael Conlon ◽  
Milena Mechkarska ◽  
Eman Ahmed ◽  
Jérôme Leprince ◽  
Hubert Vaudry ◽  
...  

Peptides ◽  
2000 ◽  
Vol 21 (11) ◽  
pp. 1673-1679 ◽  
Author(s):  
M.Luisa Mangoni ◽  
Nicoletta Grovale ◽  
Alessandra Giorgi ◽  
Giuseppina Mignogna ◽  
Maurizio Simmaco ◽  
...  

Antibiotics ◽  
2020 ◽  
Vol 9 (11) ◽  
pp. 772
Author(s):  
Maria Luisa Mangoni ◽  
Bruno Casciaro

Since the discovery of magainins from the skin secretions of the African toad Xenopus laevis by Michael Zasloff in 1987, an increasing number of antimicrobial peptides (AMPs) has been identified in different anuran species and studied in detail [...]


Antibiotics ◽  
2020 ◽  
Vol 9 (1) ◽  
pp. 24 ◽  
Author(s):  
Charles H. Chen ◽  
Timothy K. Lu

More than 3000 antimicrobial peptides (AMPs) have been discovered, seven of which have been approved by the U.S. Food and Drug Administration (FDA). Now commercialized, these seven peptides have mostly been utilized for topical medications, though some have been injected into the body to treat severe bacterial infections. To understand the translational potential for AMPs, we analyzed FDA-approved drugs in the FDA drug database. We examined their physicochemical properties, secondary structures, and mechanisms of action, and compared them with the peptides in the AMP database. All FDA-approved AMPs were discovered in Gram-positive soil bacteria, and 98% of known AMPs also come from natural sources (skin secretions of frogs and toxins from different species). However, AMPs can have undesirable properties as drugs, including instability and toxicity. Thus, the design and construction of effective AMPs require an understanding of the mechanisms of known peptides and their effects on the human body. This review provides an overview to guide the development of AMPs that can potentially be used as antimicrobial drugs.


2012 ◽  
Vol 8 (3) ◽  
pp. 416-418 ◽  
Author(s):  
Michelle G. J. L. Habets ◽  
Michael A. Brockhurst

Antimicrobial peptides (AMPs) have been proposed as a promising new class of antimicrobials despite warnings that therapeutic use could drive the evolution of pathogens resistant to our own immunity peptides. Using experimental evolution, we demonstrate that Staphylococcus aureus rapidly evolved resistance to pexiganan, a drug-candidate for diabetic leg ulcer infections. Evolved resistance was costly in terms of impaired growth rate, but costs-of-resistance were completely ameliorated by compensatory adaptation. Crucially, we show that, in some populations, experimentally evolved resistance to pexiganan provided S. aureus with cross-resistance to human-neutrophil-defensin-1, a key component of the innate immune response to infection. This unintended consequence of therapeutic use could drastically undermine our innate immune system's ability to control and clear microbial infections. Our results therefore highlight grave potential risks of AMP therapies, with implications for their development.


Soft Matter ◽  
2021 ◽  
Author(s):  
Emily Cross ◽  
Sophie M Coulter ◽  
Sreekanth Pentlavalli ◽  
Garry Laverty

The use of hydrogels has garnered significant interest as biomaterial and drug delivery platforms for anti-infective applications. For decades antimicrobial peptides have been heralded as a much needed new class...


Sign in / Sign up

Export Citation Format

Share Document